Home  |  Contact

Cellosaurus LNCaP clone FGC (CVCL_1379)

[Text version]

Cell line name LNCaP clone FGC
Synonyms LNCaP-Clone-FGC; LNCaP.FGC; LNCaP-FGC; LNCaP FGC; LNCaP-ATCC
Accession CVCL_1379
Resource Identification Initiative To cite this cell line use: LNCaP clone FGC (RRID:CVCL_1379)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Doubling time: ~34 hours (ATCC); ~36 hours (PBCF).
Microsatellite instability: Instable (MSI-high) (Sanger).
Omics: Deep exome analysis.
Omics: Deep proteome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Misspelling: LNCaP.FCG; Occasionally.
Disease Prostate carcinoma (NCIt: C4863)
Derived from metastatic site: Left supraclavicular lymph node.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0395 (LNCaP)
Children:
CVCL_U984 (AILNCaP)CVCL_W668 (LNCaP clone FGC.10)CVCL_B413 (LNCaP-17)
CVCL_B414 (LNCaP-34)CVCL_4791 (LNCaP-AI)CVCL_5J30 (LNCaP-luc-M6)
Sex of cell Male
Age at sampling 50Y
Category Cancer cell line
STR profile Source(s): AddexBio; ATCC; Cosmic-CLP; ECACC; KCLB; RCB; TKG

Markers:
AmelogeninX,Y
CSF1PO10,11
D3S135816
D5S81811,12
D7S8209.1,10.3 (AddexBio; ATCC; TKG)
11 (Cosmic-CLP)
9,11 (ECACC; KCLB)
9 (RCB)
D13S31710,12
D16S53911
FGA19,20
TH019
TPOX8,9
vWA16,18 (AddexBio; ATCC; Cosmic-CLP; ECACC; KCLB; TKG)
16,17,18 (RCB)

Run an STR similarity search on this cell line
Web pages https://physics.cancer.gov/docs/bioresource/prostate/NCI-PBCF-CRL1740_LNCaP_SOP-508.pdf
Publications

PubMed=8104329; DOI=10.1002/pros.2990230206
Carroll A.G., Voeller H.J., Sugars L., Gelmann E.P.
p53 oncogene mutations in three human prostate cancer cell lines.
Prostate 23:123-134(1993)

PubMed=11172901; DOI=10.1016/S0165-4608(00)00339-3
Strefford J.C., Lillington D.M., Young B.D., Oliver R.T.D.
The use of multicolor fluorescence technologies in the characterization of prostate carcinoma cell lines: a comparison of multiplex fluorescence in situ hybridization and spectral karyotyping data.
Cancer Genet. Cytogenet. 124:112-121(2001)

PubMed=12725112; DOI=10.1385/1-59259-372-0:21
Russell P.J., Kingsley E.A.
Human prostate cancer cell lines.
Methods Mol. Med. 81:21-39(2003)

PubMed=15833837; DOI=10.1158/0008-5472.CAN-04-3218
Lin B., White J.T., Lu W., Xie T., Utleg A.G., Yan X., Yi E.C., Shannon P., Khrebtukova I., Lange P.H., Goodlett D.R., Zhou D., Vasicek T.J., Hood L.E.
Evidence for the presence of disease-perturbed networks in prostate cancer cells by genomic and proteomic analyses: a systems approach to disease.
Cancer Res. 65:3081-3091(2005)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23325432; DOI=10.1101/gr.147942.112
Varley K.E., Gertz J., Bowling K.M., Parker S.L., Reddy T.E., Pauli-Behn F., Cross M.K., Williams B.A., Stamatoyannopoulos J.A., Crawford G.E., Absher D.M., Wold B.J., Myers R.M.
Dynamic DNA methylation across diverse human cell lines and tissues.
Genome Res. 23:555-567(2013)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

Cross-references
Cell line collections AddexBio; C0019003/4953
ATCC; CRL-1740
BCRC; 60088
BCRJ; 0149
ECACC; 89110211
ICLC; HTL99011
IZSLER; BS TCL 148
KCB; KCB 200732YJ
KCLB; 21740
RCB; RCB2144
TKG; TKG 0603
Cell line databases/resources CLDB; cl3245
CLDB; cl4960
CLDB; cl5222
CCLE; LNCAPCLONEFGC_PROSTATE
CCRID; 3131C0001000700031
Cell_Model_Passport; SIDM00683
Cosmic-CLP; 907788
GDSC; 907788
Ontologies BTO; BTO:0006095
CLO; CLO_0007366
CLO; CLO_0007367
CLO; CLO_0051537
EFO; EFO_0005726
Biological sample resources 4DN; 4DNSR4OQOB67
BioSample; SAMN03471417
BioSample; SAMN03472018
BioSample; SAMN05292444
ENCODE; ENCBS235TSM
ENCODE; ENCBS386ENC
ENCODE; ENCBS387ENC
ENCODE; ENCBS418ENC
ENCODE; ENCBS422ENC
Chemistry resources ChEMBL-Cells; CHEMBL3308342
ChEMBL-Targets; CHEMBL2366172
Gene expression databases ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM651578
GEO; GSM651579
GEO; GSM827569
GEO; GSM887271
GEO; GSM888346
GEO; GSM1670051
Other Wikidata; Q54902825
Polymorphism and mutation databases Cosmic; 688117
Cosmic; 907788